anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
MiR-142-3p has recently emerged as key factor in tailoring personalized treatments for multiple sclerosis (MS), a chronic autoimmune demyelinating disease of the central nervous system (CNS) with heterogeneous pathophysiology and an unpredictable course. With its involvement in a detrimental regulatory axis with interleukin-1beta (IL1β), miR-142-3p orchestrates excitotoxic synaptic alterations that significantly impact both MS progression and therapeutic outcomes. In this study, we investigated for the first time the influence of individual genetic variability on the miR-142-3p excitotoxic effect in MS. We specifically focused on the single-nucleotide polymorphism Val66Met (rs6265) of the brain-derived neurotrophic factor (BDNF) gene, known for its crucial role in CNS functioning. We assessed the levels of miR-142-3p and IL1β in cerebrospinal fluid (CSF) obtained from a cohort of 114 patients with MS upon diagnosis. By stratifying patients according to their genetic background, statistical correlations with clinical parameters were performed. Notably, in Met-carrier patients, we observed a decoupling of miR-142-3p levels from IL1β levels in the CSF, as well as from of disease severity (Expanded Disability Status Score, EDSS; Multiple Sclerosis Severity Score, MSSS; Age-Related Multiple Sclerosis Severity Score, ARMSS) and progression (Progression Index, PI). Our discovery of the interference between BDNF Val66Met polymorphism and the synaptotoxic IL1β-miR-142-3p axis, therefore hampering miR-142-3p action on MS course, provides valuable insights for further development of personalized medicine in the field.
PURPOSE: A manufacturing method of microsphere - hydro gel composite in which growth factor protein is dipped is provided to omit sterilization process or organic solvent use in conventional protein drug delivery formulation to resolve problems followed by the sterilization process or organic solvent. CONSTITUTION: A manufacturing method of microsphere - hydro gel composite in which growth factor protein is dipped comprises the following steps: preparing porous B-TCP microsphere; dipping the growth factor protein in the microsphere; and obtaining a composite of poloxamer hydro gel and porous B-TCP microsphere by mixing the porous B-TCP microsphere with temperature sensitive poloxamer hydro gel using 3-way connector. The sintering temperature of the porous B -TCP microsphere is 1050-1250 deg. Celsius, and the initial concentration before mixing the poloxamer hydro gel with the microsphere is 33-37 wt%. The porous B -TCP microsphere has particle size of 45-75 micro meters. The sintering temperature of the porous B -TCP microsphere is 1050 deg. Celsius, and the initial concentration is 35 wt%. The porous B -TCP microsphere and poloxamer hydro gel are mixed at the same mass. [Reference numerals] (AA) BMP-2 load porous microsphere; (BB) High concentration poloxamer hydrogel; (CC) Mixing by using 3 way connector; (DD) Microsphere-hydrogel carrier which loads the BMP-2
FIELD: veterinary science, biotechnology, immunology. SUBSTANCE: method of preparing the dried semiproduct of anti-anthrax globulin involves additional addition of polyclucin sucrose to 8.5-9.5% solution of immunoreactive gamma- and beta-globulin fractions isolated from the equine blood serum proteins in the ratio of components = 92.5 : 0.5 : 7.0 wt.%. Invention provides the increase of storage period of globulin semiproduct before its processing to the ready preparation at simultaneous retention of its quality indices of the ready preparation determined by normative standards for equine anti-anthrax liquid globulin. Obtained substance is dried by the sublimation method. Invention can be used for stabilization of physical-chemical and immunobiological properties of anti-anthrax globulin semiproducts. EFFECT: increased period of storage of semiproduct. 2 tbl
Nasopharyngeal carcinoma is one of the most common malignancies in South China. Nasopharyngeal carcinoma is sensitive to radiotherapy and chemotherapy. Concurrent chemoradiation has become a standard treatment for locally advanced stage III-IVb nasopharyngeal carcinoma. However, The recommended single-agent DDP concurrent chemotherapy regimen for high-risk patients (IVa-IVb period) to improve the efficacy was not significant. Paclitaxel combined with platinum in the same period of chemotherapy regimen has been widely used in head and neck cancer, cervical cancer, esophageal squamous cell carcinoma and lung cancer and other tumors, a number of studies have shown that it has good tolerance and efficacy. And a number of previous studies have shown that paclitaxel combined with platinum chemotherapy in the same period of head and neck cancer or nasopharyngeal cancer in multiple phase II clinical trials to achieve encouraging results. Based on the above background and basis, for the high risk (IVa-IVb) nasopharyngeal carcinoma treatment, the applicant intends to carry out the first IMRT + paclitaxel + DDP concurrent chemotherapy compared with DDP single drug concurrent chemotherapy regimen Pharyngeal cancer in a prospective randomized controlled phase Ⅱ clinical trial for paclitaxel + DDP dual-chemotherapy regimen for the treatment of high-risk nasopharyngeal carcinoma to provide evidence-based basis. (IVa-IVb) nasopharyngeal carcinoma (NPC), and to provide a high-level evidence-based evidence-based approach to the treatment of nasopharyngeal carcinoma at high risk (stage IVa-IVb). The results of this study will be used in international guidelines to optimize high- Treatment of cancer patients.
Before a tDCS protocol applied during de mental practice training , the patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
Women who use Medroxyprogesterone Acetate Injectable Suspension, USP may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be completely reversible.

It is unknown if use of Medroxyprogesterone Acetate Injectable Suspension, USP during adolescence or early adulthood, a critical period of bone accretion, will reduce peak bone mass and increase the risk for osteoporotic fracture in later life.

Medroxyprogesterone Acetate Injectable Suspension, USP should be used as a long-term birth control method (e.g. longer than 2 years) only if other birth control methods are inadequate. (See WARNINGS.)
The embodiments herein relate to a system and method for detecting an internal object in a body under test. The system comprises at least one antenna which are adapted to be positioned around the body under test. The system is adapted to transmit radio frequency signal(s) into the body under test which are reflected and/or scattered from the internal object. The system is adapted to receive the reflected and/or scattered radio frequency signal(s) and use a method of classification S1-S7 to determine the presence of an internal object. The system is adapted to detect the internal object or a change in an already detected internal object when there is a difference between the received radio frequency signals. The difference is related to the different dielectric properties between the internal object and the body under test.
Participants will have a nasopharyngeal swab sample collected by trained study site personnel for testing on a high sensitivity EUA SARS-CoV-2 RT-PCR assay to compare the result to the result of the iCura SARS-CoV-2 Antigen Rapid Home Test. The participant will then self-collect or, if both are over 18, collect from another study participant an anterior nasal swab sample and test using the iCura SARS-CoV-2 Antigen Rapid Home Test.
Rheumatoid arthritis (RA) is a common autoimmune disease, and some observational studies have indicated an association between Gastroesophageal Reflux Disease (GERD) and RA. However, the causal relationship between the two remains uncertain. We used Mendelian randomization (MR) to assess the causal relationship between GERD and RA. Two-sample Mendelian randomization analysis was performed using pooled data from large-scale genome-wide association studies. In addition, we performed multivariate MR analyses to exclude confounding factors between GERD and RA, including smoking quantity, drinking frequency, BMI, depression, and education attainment. The MR results for GERD on RA suggested a causal effect of the genetic susceptibility of GERD on RA (discovery dataset, IVW, odds ratio [OR] = 1.41, 95% confidence interval [CI] 1.22-1.63, p = 2.81 × 10-6; validation dataset, IVW, OR = 1.38, 95% CI 1.23-1.55, P = 1.76 × 10-8). Multivariate MR analysis also supports this result. But the results of the reverse MR analysis did not reveal compelling evidence that RA can increase the risk of developing GERD. Our bidirectional Two-Sample Mendelian randomization analysis and multivariate MR analysis provide support for the causal effect of GERD on RA. This discovery could offer new insights for the prevention and treatment of RA.
Patients in the standard arm will receive a conventional radiotherapy dose will be either 30 gray (Gy) in 10 fraction or 20Gy in 5 fractions. Patients will be stratified by intended dose prior to randomization. Radiation for patients in the standard arm should adhere to the principles of palliative radiation, with goals of alleviating symptoms or preventing potential complications.
High-dose right modified unilateral ECT twice weekly at 6 times the seizure threshold. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0mg/kg) for muscle relaxation.
Participants in this arm engage in an 8-week program that integrates mindful eating and mindful movement practices into their regular physical education classes. Each class includes a 10-minute mindful eating practice focused on enhancing awareness of hunger and fullness cues, sensory experiences of food, and emotional responses to eating. Following this, the final 10 minutes of each class are dedicated to mindful movement exercises, which combine physical postures and movement with mindfulness techniques to promote food literacy, physical literacy and social emotional competencies.
PURPOSE:To enable the gelation from sol state on standing by the titled composition by incorporating 0.005-20%, based on the water content, carrageenan to prepare a composition of reversibly generating sol by the exertion and release of external force. CONSTITUTION:The composition is prepared by incorporating 0.005-20% carrageenan into >=70% water content. For example, a 0.2% aq. soln. of iota- carrageenan whose contercations are mostly formed with calcium is prepared and the soln. is kept at about 1 deg.C in a refrigerator. The soln. is in the form of a weak gel and can be gelated to the extent that the gel can be sufficiently scooped with a spoon. When the weak gel is placed in a vessel, kept at 1 deg.C and strongly shaked with the hand, an extremely fluidized liq. can be obtained. When the liq. is kept at 1 deg.C in a refrigerator, the liq. is again gelated.
Little is known about motivators and barriers for physical activity after hospital discharge for patients with a minor stroke or TIA. These patients have few and temporary symptoms and are therefore discharged early from the hospital or seen in a outpatient TIA clinic. Standard treatment are preventive medication and advice on self-managed lifestyle changes. Occurrence of one ischemic stroke or TIA predisposes to further ischemic strokes and patients are at risk of developing cognitive deficits or vascular dementia over time unless multiple preventive measures are taken including physical activity. The purpose is to investigate motivators and barriers for physical activity after hospital discharge by focus-group interviewing this potential fragile group of patients. The research team want to facilitate the patients to be physically active and thereby prevent a recurrent stroke and slow the progression of vascular diseases.
PCT No. PCT/IB95/00019 Sec. 371 Date Jun. 28, 1996 Sec. 102(e) Date Jun. 28, 1996 PCT Filed Jan. 10, 1995 PCT Pub. No. WO95/09657 PCT Pub. Date Apr. 13, 1995The invention relates to a pharmaceutical preparation comprising a plasma protein wherein said preparation is free of infectious agents as well as essentially free of denaturation products and is obtainable by a method that encompasses the following steps: a) addition of a polyether and a chaotropic agent to a solution comprising the plasma protein, optional lyophilization of the solution; b) inactivation of infectious agents in the presence of the polyether by a physio-chemical or chemical treatment, and c) removal of the polyether and the chaotropic agent.
This randomized (study medication assigned to participants by chance), multicenter study will provide study treatment (atezolizumab alone or atezolizumab+daratumumab) to participants with previously treated advanced or metastatic NSCLC to assess the anti-tumor activity and safety. Participants who receive atezolizumab treatment with confirmed disease progression based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 will be eligible to crossover to treatment (atezolizumab + daratumumab) if they meet crossover eligibility criteria. It is expected that 100 participants will enroll in the study including 6 participants in the safety run in phase. Data Monitoring Committee (DMC) will review ongoing data, and may formulate recommendations on study conduct, including expansion of enrollment of some PD-L1 subgroups, resulting in greater than 96 participants. The participants in the safety run in phase will be administered the combination of daratumumab and atezolizumab to determine the safety and tolerability that will be evaluated by the Safety Evaluation Team (SET) for dose limiting toxicity before the random assignment of participants in a 1:1 ratio in 2 treatment arms. The study consists of 3 phases: Screening Phase (up to 28 days), Treatment Phase and Post-Treatment Follow-up Phase which will continue until death, lost to follow-up, withdrawal of consent, or the End of the Study \[the study end is approximately 6 to 12 months after that last participant is enrolled\]. Participants will undergo tumor assessments (RECIST 1.1), immunogenicity, pharmacokinetics, biomarkers and safety evaluations (adverse events, laboratory tests, electrocardiogram \[ECGs\], vital sign measurements, physical examinations, Eastern Cooperative Oncology Group \[ECOG\] performance status score) over the time.
The invention provides an external pain-relieving ointment and a preparation method thereof. The ointment has little side and toxic effect, is made of traditional Chinese herbals, can be applied on the affected parts externally, has a good pain-relieving effect, and is very convenient to use. The ointment can be smeared on the skin to moisten the skin, is capable of maintaining the optimal state of skin tissues of wounds, and promotes the self-repairing process of skin. Furthermore, the ointment cuts off the contact between the bacteria in the air and the skin, and thus reduces the possibility of infection. The ointment is nonirritant and stable, is not easy to degrade, will not cause allergy, and is especially suitable for people who are allergic to cosmetic additives such as essences, alcohol, and the like. The ointment contains tea seed oil, which contains vitamin E and antioxidant components, so the ointment can protect skin, prevent skin damage and aging, and make skin smooth and bright, and moreover, the ointment can treat chloasma and sunburn.
Following implementation of protocol amendment- 5 and 6, all participants will receive JNJ-73763989 subcutaneously along with NA (tenofovir disoproxil tablets orally) for 36 weeks (induction phase). In the consolidation phase, participants will receive PegIFN-alpha-2a subcutaneously in addition to JNJ-73763989 and NA for 12 weeks. According to predefined criteria NA treatment may be continued during the follow up (FU) phase. JNJ-56136379 (JNJ-6379) was discontinued as per amendment 6 of the study.
This drug combination provides phenobarbital combined with belladonna alkaloids in a specific, fixed ratio to provide anticholinergic/antispasmodic action and mild sedation.

Phenobarbital is a barbiturate, nonselective central nervous system depressant. It is primarily used as a sedative hypnotic and also as an anticonvulsant in subhypnotic doses. 

Atropine Sulfate, Hyoscyamine Sulfate, and Scopolamine are belladonna alkaloids classified as anticholinergic, antimuscarinic drugs. They act to inhibit muscarinic actions of acetylcholine at postganglionic parasympathetic neuron effector sites. These drugs are also used as antispasmodics due to their anticholinergic action. They produce the effect in the body of reduced muscle spasms in the digestive or urinary tract, and reduced fluid secretions from certain glands or organs.
The invention discloses a model based on machine learning-radiomics which is a Nomogram model; the establishment of said Nomogram model comprising following steps: S1. collecting data and predicting factor selection; S2. combining selected 6 radiomics characteristics according to contribution weighting, developing a rad-score model; S3. establishing different diagnosis models, comparing performances of the diagnosis models in the diagnosis of osteoporosis and osteopenia, wherein said diagnosis models comprise: Clinics model, Radiomics model, and Combined model; S4. performing visualization processing on combined model by using the “rms” packet in R software to obtain Nomogram model; S5. validation of the Nomogram model. The invention combines characteristics of the radiomics and clinical risk factors to establish a combined Nomogram model to diagnose conditions of osteoporosis and osteopenia of patients. The diagnosis method can accurately distinct patients with osteoporosis from patients with osteopenia, having great application value for selection of clinical therapeutic regimen.
Screening Meal Test performed and subject meets criteria for Postprandial Hypotension. During the second Meal Test subject will receive Acarbose 50mg and will take Acarbose 25mg with first bite of each of the next 3 meals.
In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. The nerves are then "cleaned up" to enhance the possibility of healthy healing. The surgeon will then identify a local muscle along with a small artery and vein that supply blood to part of the muscle. A small sample of muscle, still attached to the artery and vein, is then created. The nearby nerves are then nestled into this segment of muscle that is still connected to the artery and vein. This is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 2 - 4 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain.
The present invention relates to a traditional Chinese medicine preparation for treating hyperplasia of mammary glands and a preparation method thereof. Ingredients comprise processed shelling castor bean powder, and crimson melanterite, etc. can also be added to the ingredients. The preparation method comprises the following working procedures: processing castor beans, weighing the castor beans, preparing the preparation, etc. With the advantage of convenience for preparing and taking, the traditional Chinese medicine preparation has the functions of stagnated liver qi dispersion for relieving qi stagnation, hard mass softening and resolving, blood circulation activation and blood stasis dissipation. Toxicological experimental results show that the traditional Chinese medicine preparation also has the advantages of safety, no toxic or side effect, small dose, short treatment course, rich medicine source, low cost and good curative effect, and the traditional Chinese medicine preparation has special effects for treating hyperplasia of mammary glands.
For some deaf people, sign language is the preferred language, the one in which they feel most comfortable. However, there are very few assessment tools developed or adapted for sign languages. The aim of this study was to translate and adapt in Italian Sign Language (LIS) the Italian version of the Youth Quality of Life Instrument-Deaf and Hard of Hearing Module (YQOL-DHH). The YQOL-DHH is a questionnaire assessing health-related quality of life in young deaf people. The guidelines provided by the authors of the original version were followed. Further controls and changes were made to take into account variability in signers' linguistic skills. This work and availability of the YQOL-DHH questionnaire in LIS, in addition to the Italian version, will ensure accessibility for Italian deaf adolescents.
This is a Phase 1, open-label, multiple-dose trial conducted at a single center. The treatment period will consist of three 6 g doses (18 g) of ZTI-01 as a 1-hour intravenous (IV) infusion (+10 minute window). A total of 30 enrolled subjects will be randomized to undergo a single standardized bronchoscopy with bronchoalveolar lavage (BAL) at one of five sampling times. A total of 6 subjects will be assigned to each BAL-sampling time. Up to ten additional enrolled subjects will act as alternates to obtain 30 evaluable subjects. An evaluable subject is defined as a subject who receives all doses of ZTI-01, undergoes BAL at the randomized sampling timepoint with BAL return volume adequate for testing, and undergoes at least the one blood sampling timepoint that is concurrent with the assigned BAL sampling timepoint, with blood sampling volume that is adequate for testing. The objectives of the study are to assess safety and pharmacokinetics (PK) for a multiple dose regimen of IV-infused ZTI-01.
Pneumonia is the main cause of death in Human Immunodeficiency Virus (HIV)-infected children. A significant number of undiagnosed or poorly treated HIV-infected children present to health services with severe pneumonia. World Health Organization (WHO) guidelines to treat severe pneumonia in HIV-infected infants include empirical treatment against common bacteria plus Pneumocystis jirovecii. Although this approach has contributed to reducing overall case fatality rates, mortality in this particularly vulnerable group remains unacceptably high. Autopsy studies in Africa have shown that cytomegalovirus (CMV) infection and tuberculosis (TB) are important underdiagnosed and undertreated causes of deaths. Our objective is to evaluate whether empirical treatment against cytomegalovirus and tuberculosis improves survival of HIV-infected infants with severe pneumonia. A randomized factorial clinical trial will be conducted in six sub-Saharan African countries to evaluate the safety and efficacy of empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants aged 28 days to 365 days admitted to hospital with severe pneumonia. The primary outcome is mortality. All HIV-infected infants will receive standard of care (SoC) pneumonia treatment, including antibiotics, cotrimoxazole, and prednisolone. A group of patients will receive SoC, another group will receive valganciclovir plus SoC, another group will receive tuberculosis treatment plus SoC, and another group will receive valganciclovir, tuberculosis treatment, and SoC.